Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Neoplasms 7Multiple Myeloma 4Sarcoma 3Leukemia 3Kidney Neoplasms 3Glioma 3Brain Neoplasms 3Waldenstrom Macroglobulinemia 2Sarcoma, Alveolar Soft Part 2Recurrence 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Oligodendroglioma 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Glioblastoma 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Astrocytoma 2Unspecified Adult Solid Tumor, Protocol Specific 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Sarcoma, Synovial 1Sarcoma, Endometrial Stromal 1Salivary Gland Neoplasms 1Rhabdomyosarcoma 1Ovarian Neoplasms 1

Interventions

Dexamethasone 809Bortezomib 449Lenalidomide 430Cyclophosphamide 336Melphalan 251Calcium Dobesilate 237daratumumab 218pomalidomide 202carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67isatuximab 64Prednisone 64dexamethasone 21-phosphate 63elotuzumab 60auricularum 57belantamab mafodotin 55Antilymphocyte Serum 55Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Multiple Myeloma × perifosine × Clear all
NCT00375791 2018-02-28

Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma

AEterna Zentaris

Phase 2 Completed
67 enrolled
Plasma cell

Multiple Myeloma

NCT00401011 2018-02-23

Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients

AEterna Zentaris

Phase 1/2 Completed
84 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT01002248 2018-02-09

Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

AEterna Zentaris

Phase 3 Terminated
135 enrolled
Plasma cell

Multiple Myeloma

NCT00415064 2012-07-06

Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma

AEterna Zentaris

Phase 1 Completed
32 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡